Revumenib in Patients With Myelofibrosis
Key claim: A Phase Ib/II study is testing safety and efficacy of revumenib alone after prior JAK-inhibitor therapy and then combined with a JAK inhibitor in patients with myelofibrosis.
Abstract
This is a Phase Ib/II 2 study investigating the safety and efficacy of revumenib in two cohorts of participants with myelofibrosis. COHORT-1 will investigate the safety of revumenib as monotherapy in participants with myelofibrosis previously treated with a JAK inhibitor. Following confirmation of safety in COHORT-1, the study will proceed with enrollment in COHORT-2, which will evaluate the efficacy and safety of revumenib in combination with a JAK inhibitor.
Why this matters
Menin inhibitors like revumenib are established in KMT2A-rearranged and NPM1-mutant AML, and extending them into myelofibrosis tests whether menin-MLL axis blockade can address JAK-inhibitor-refractory disease either alone or in combination. This is one of several efforts to repurpose AML-class agents for advanced MPN, alongside BET, BCL-2, and MDM2 inhibitors already tracked in this area.